ReviewVaccine2013
Monoclonal antibodies for prophylactic and therapeutic use against viral infections.
Review in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.Antimicrobial agents and chemotherapy · 2018Trial
- Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.Antimicrobial agents and chemotherapy · 2017Trial
- Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.Antimicrobial agents and chemotherapy · 2016Trial
- Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.Antimicrobial agents and chemotherapy · 2015Trial
- A neuraminidase-targeting nanobody as a therapeutic candidate against influenza A and B viruses.Journal of virology · 2026Article
- mRNA-Encoded Antibodies: An Emerging Paradigm in Antiviral Protection.Biomolecules · 2026Review
- Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants.Frontiers in immunology · 2026Article
- Protection against lethal HAdV-4 challenge in STAT1 mice by novel human monoclonal antibodies.Frontiers in immunology · 2025Article
- A novel antibody treatment reduces deformed wing virus loads in the western honey bee (mSphere · 2024Article
- Development of Human Monoclonal Antibodies With Broad Reactivity for Rabies Postexposure Prophylaxis.Journal of medical virology · 2024Article
- Review
- Viral Factors in Modulation of Host Immune Response: A Route to Novel Antiviral Agents and New Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.bioRxiv : the preprint server for biology · 2023Article
- Efficiency Comparative Approach of Plant-Produced Monoclonal Antibodies against Rabies Virus Infection.Vaccines · 2023Article
- Characterisation of a Live-Attenuated Rabies Virus Expressing a Secreted scFv for the Treatment of Rabies.Viruses · 2023Article
- A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant.Plant biotechnology journal · 2023Article
- Prevention and management of CMV infection in pediatric solid organ transplant recipients.Frontiers in pediatrics · 2023Review
- A humanized anti-human adenovirus 55 monoclonal antibody with good neutralization ability.Frontiers in immunology · 2023Article
- Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus.NPJ vaccines · 2022Article
- Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly being replaced by highly potent monoclonal antibodies (mAbs). Cocktails of mAbs and bispecific constructs can be used to simultaneously target multiple viral epitopes and to overcome issues of neutralization escape. Advances in antibody engineering have led to a large array of novel mAb formats, while deeper insight into the biology of several viruses and increasing knowledge of their neutralizing epitopes has extended the list of potential targets. In addition, progress in developing inexpensive production platforms will make antiviral mAbs more widely available and affordable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.